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Side and time variability of intraepidermal
nerve fiber density
ABSTRACT
Objective: To assess the right-to-left and short-term variability of intraepidermal nerve fiber
density (IENFD) at the distal site of the leg.
Methods: Patients with possible or probable small fiber neuropathy (SFN) and healthy volunteers
(HVs) underwent skin biopsies at the right and left distal leg. A subgroup of participants under-
went follow-up biopsies 20 days later. Biopsies were immunostained by polyclonal anti-protein
gene product 9.5 antibodies, and IENFD was quantified in nonconsecutive sections following
published guidelines by operators blinded to the participants’ condition (diagnosis, side, and time
of biopsy). Findings were referred to sex- and age-adjusted normative values.
Results: Forty patients and 17 HVs underwent bilateral skin biopsies; 15 patients and 8 HVs
underwent follow-up skin biopsies. Sural nerve and dorsal sural nerve conduction studies were
normal in all participants. Interside IENFD did not differ both in patients (median 2.45 IENF/
mm 6 1.45 SD right; 2.2 IENF/mm 6 1.32 SD left) and HVs (median 6.3 IENF/mm 6 2.81 right;
6.2 IENF/mm 6 2.3 SD left). The right-to-left correlation coefficients were excellent (Pearson
0.95 in SFN and 0.97 in HVs). The analysis of IENFD at 20-day follow-up biopsy showed no
difference between sides in both groups and yielded excellent correlation coefficients.
Conclusions: The diagnosis of SFN can be reliably ascertained by unilateral skin biopsy at the distal
site of the leg, and IENFD is not expected to vary within 3 weeks. Neurology® 2015;84:2368–2371
GLOSSARY
HV 5 healthy volunteer; IENF 5 intraepidermal nerve fiber; IENFD 5 intraepidermal nerve fiber density; SFN 5 small fiber
neuropathy.
Intraepidermal nerve fiber density (IENFD) at the distal site of the leg is a widely used tool to
confirm the diagnosis of small fiber neuropathy (SFN).1 The availability of age- and sex-adjusted
reference values has improved the reliability of the method based on bright-field immunohis-
tochemistry.2 Skin biopsy, like electrodiagnostic studies, is usually performed unilaterally, and
no recommendation currently exists to perform it on the right or left side for diagnosing SFN.
However, while the right-to-left concordance of sural nerve conduction velocity and amplitude
has been investigated in patients with neuropathy and healthy volunteers (HVs),3 it is unknown
whether this variable can affect the diagnostic performance of skin biopsy. One further variable
is the consistency of IENFD over a short period of time. Skin is a self-renewal tissue, and the
epidermis has an active turnover estimated at about 40 days.4 The loss of IENF, which is the
hallmark of SFN, can modify the architecture of the epidermis and possibly of keratinocyte
functioning, which are part of the complex peripheral network involved in thermal sensation
and nociception.5 It is unknown whether epidermis turnover can influence IENFD in neurop-
athy and HVs. Our study aimed at addressing the right-to-left and time variability of IENFD
over a period of 20 days, namely, the estimated half-life for the complete epidermis renewal, in
patients with SFN and HVs. Our results strengthen the robustness of skin biopsy in diagnosing
SFN and support its use as a biomarker in clinical trials.
From the 3rd Neurology Unit and Skin Biopsy (G.L., P.D., R.L., D.C., C.P.-S., M.T., J.S., E.D.B.), Peripheral Neuropathy and Neuropathic Pain
Clinic, IRCCS Foundation Carlo Besta Neurological Institute, Milan; and Neurological Unit (S.R., C.L., R.E., G.D.), University Hospital S. Maria
della Misericordia, Udine, Italy.
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METHODS Consecutive patients referred for a skin biopsy
to confirm the diagnosis of possible or probable symmetric
SFN according to published criteria6 were enrolled. All patients
underwent a thorough screening for known causes of SFN.
HVs recruited among hospital employers and patients’ relatives
were asked to participate. Inclusion criteria for HVs were no
symptoms or risk factors for neuropathy and a normal neuro-
logic examination. Exclusion criteria for both groups were anti-
coagulant treatment, known bleeding disorders, and local skin
infections. All participants underwent skin biopsies at the right
and left distal leg, 10 cm above the external malleolus within
the territory of the sural nerve. A subgroup of participants was
asked to undergo follow-up biopsies 20 days later 2 to 3 mm
apart from the scar of the prior biopsy. All biopsies were taken
using a disposable 3-mm punch, under sterile technique, and
after topical anesthesia with spray ice. No suture was needed.
The immunostaining procedure was performed following
published guidelines using polyclonal anti-protein gene
product 9.5 antibodies (UltraClone Ltd., Isle of Wight,
UK).1 Briefly, specimens were fixed (2% paraformaldehyde-
lysine-sodium periodate, 4°C overnight), cryoprotected, and
serially cut with a cryostat. Each 3-mm punch biopsy yielded
about 45 vertical 50-mm sections. To decrease the variability of
section length, IENFD was quantified on 3 nonconsecutive
central sections (e.g., no. 25, 27, 29). All fibers crossing the
dermal–epidermal junction, excluding fragments and
secondary branching, were counted and their number was
divided by the length of the epidermis to obtain a linear
density (IENF/mm). Counts were performed by 2 expert
operators blinded to conditions (diagnosis, side, and time of
biopsy). IENFD was compared with sex- and age-adjusted
normative values.2
Table 1 Demographic data and IENFD values at the right and left distal site of the leg and corresponding
values at the follow-up skin biopsy performed at 20 days in patients with SFN and healthy volunteers
Participant no. Age, y Sex Diagnosis Right IENFD Right IENFD 20 d Left IENFD Left IENFD 20 d 5th percentile
2 32 M SFN 3.5 3.8 ND ND ND
22 59 M SFN 1.7 1.9 1.6 1.6 3.5
23 24 F SFN 2.7 2.7 ND ND 8.4
26 41 M SFN 2.2 2.1 2.1 2.1 4.4
27 46 M SFN 3.2 2.9 3.3 2.7 4.4
28 52 F SFN 2.1 2.2 2.3 2.1 4.3
29 61 F SFN 1.1 1.2 1.2 1.0 3.2
30 22 F SFN 2.5 2.4 ND ND 8.4
31 59 M SFN 1.6 1.7 ND ND 3.5
33 44 M SFN 1.5 1.6 1.3 1.3 4.4
34 73 M SFN 1.2 1.3 1.4 1.4 2.1
35 79 M SFN 1.5 1.6 1.8 1.8 2.1
36 49 F SFN 2.1 2.0 2.2 2.1 5.7
37 38 F SFN 0.8 1.0 0.8 1.2 7.1
Mean 2.0 2.0 1.8 1.7 —
Median 1.9 2.0 1.7 1.7 —
SD 0.8 0.7 0.7 0.5 —
Pearson 0.98 0.96 —
45 63 M Healthy 3.6 3.8 ND ND 2.8
46 75 F Healthy 11.6 11.2 8.9 9.0 2.2
47 72 M Healthy 3.8 3.4 ND ND 2.1
50 75 M Healthy 4.2 3.9 ND ND 2.1
52 44 M Healthy 6.8 6.5 6.5 5.8 4.4
56 70 M Healthy 3.5 3.6 3.3 3.6 2.1
54 51 F Healthy 3.8 3.5 3.8 3.3 4.3
57 58 F Healthy 6.3 6.2 6.2 6.0 4.3
Mean 5.5 5.3 5.7 5.5 —
Median 4.0 3.9 6.2 5.8 —
SD 2.8 2.7 2.3 2.3 —
Pearson 1.00 0.98 —
Abbreviations: IENFD 5 intraepidermal nerve fiber density; ND 5 not done; SFN 5 small fiber neuropathy.
Participants’ number corresponds to that of table e-1.
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Standard protocol approvals, registrations, and patient
consents. The study was approved by the local ethic committees,
and each participant was enrolled after giving written informed
consent.
Statistical analysis. Data were presented using descriptive
statistics, and comparison between groups was performed using
parametric or nonparametric statistics where appropriate. Analy-
ses were conducted using the Stata 9 software (StataCorp, College
Station, TX).
RESULTS Forty eligible patients and 17 HVs were
enrolled, and skin biopsy was performed bilaterally
(table e-1 on the Neurology® Web site at
Neurology.org). Fifteen patients with SFN and 8
HVs underwent follow-up biopsies (bilaterally in 11
and 5, respectively) (table 1). Patients did not report
any change of symptoms between baseline and
follow-up biopsy, and the neurologic examination
was unchanged. At baseline, all patients with SFN
and HVs showed normal sural nerve action
potential amplitudes bilaterally (.10 mV in those
younger than 60 years and .6 mV in those
60 years and older). Dorsal sural nerve action
potential was recorded in 11 patients with SFN and
6 HVs, showing normal amplitude (.2.5 mV) and
mean sural nerve action potential/dorsal sural nerve
action potential ratio (.3).7
In patients with SFN, mean and median IENFD
values were 2.45 IENF/mm and 2.3 IENF/mm 6
1.45 SD at the right side, and 2.4 IENF/mm and 2.2
IENF/mm 6 1.32 SD at the left side, a nonsignifi-
cant difference. In 35 of 40 patients, IENFD was
bilaterally below the fifth percentile. Among the re-
maining patients, only 2 (no. 15 and 18; idiopathic
SFN) had IENFD bilaterally about 30% higher than
the cutoff, thus not confirming the diagnosis of SFN
pathologically, whereas the others (no. 4, 9, 10)
showed values at the cutoff, making the diagnosis
possible pathologically. In HVs, mean and median
values of IENFD were 6.38 IENF/mm and 6.3
IENF/mm 6 2.81 SD at the right side, and 6.0
IENF/mm and 6.2 IENF/mm 6 2.3 SD at the left
side, a nonsignificant difference. In 15 of 17 HVs,
IENFD was bilaterally above the fifth percentile. Of
the remaining 2 HVs, one (no. 54) had IENFD about
10% lower than the cutoff, whereas the other (no. 53)
had IENFD at the cutoff (table e-1). The right-to-left
correlation of IENFD computed for all participants
was excellent (figure). The correlation analysis
between IENFD at baseline and 20-day follow-up
was performed in 15 patients with SFN and 8 HVs
(table 1). Mean and median values did not differ
between sides and the linear regression analysis
yielded an excellent correlation (figure).
DISCUSSION Skin biopsy performed using a 3-mm
disposable punch is safe and minimally invasive,
with minor side effects in ,2/1,000 individuals.1 It
can be easily repeated in the same area for follow-up
studies because of the lack of IENFD variability
between counts obtained from close biopsies in
the same sensory nerve territory.8 However, the
variability of IENFD between the right and left
distal leg and within a 20-day frame, which is the
half-time of epidermis renewal, has not been
investigated to date. We demonstrate that the value
of IENFD is independent of the side where biopsy is
performed and, likely, epidermis turnover. If IENFD
was affected by the turnover of keratinocytes, a
follow-up biopsy at their half-life of renewal should
have captured any related change. In the absence of
any factor that can vary IENFD, such as neuropathy
progression, biopsy in a different sensory nerve
territory, technical issues in biopsy processing
section, and number of sections quantified,9 any
significant change would be attributed to intrinsic
skin variables. Since we used the bright-field
method and not indirect immunofluorescence,10 we
Figure Side and time correlation of IENFD at the distal leg
Linear regression analyses demonstrating the excellent right-to-left correlation of intraepi-
dermal nerve fiber density (IENFD) in (A) 40 patients with small fiber neuropathy and 17
healthy volunteers, and (B) between baseline and 20-day follow-up biopsy on both sides in
15 patients with small fiber neuropathy and 8 healthy volunteers.
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did not reassess intra- and interobserver agreement on
IENFD quantification, knowing its excellent results
have already been published.1
Our results, showing overlapping values and excel-
lent correlation coefficients for IENFD quantification
both in HVs and patients with SFN, confirmed that
skin biopsy can be performed unilaterally to assess the
diagnosis of SFN in individual patients and that
IENFD can be reliably used as a biomarker of small
nerve fiber degeneration within a 3-week period.
These findings can strengthen the use of skin biopsy
also as outcome measure in clinical trials.
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